|
๐ฌ
|
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors
F. Ossendorp,
E. Mengede,
M. Camps,
Rian Filius,
C. Melief
|
9 |
1998 |
9
๐ฌ
|
|
๐
|
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
8 auth.
M. Fransen,
M. Schoonderwoerd,
P. Knopf,
M. Camps,
L. Hawinkels,
M. Kneilling,
...
T. van Hall,
F. Ossendorp
|
8 |
2018 |
8
๐
|
|
๐
|
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and Tโcell activation
18 auth.
Rodney A. Rosalia,
E. Quakkelaar,
A. Redeker,
Selina Khan,
M. Camps,
J. Drijfhout,
A. L. Silva,
W. Jiskoot,
T. van Hall,
P. V. van Veelen,
...
G. Janssen,
K. Franken,
L. Cruz,
A. Tromp,
J. Oostendorp,
S. H. van der Burg,
F. Ossendorp,
C. Melief
|
7 |
2013 |
7
๐
|
|
๐
|
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants
22 auth.
T. Hall,
E. Wolpert,
P. Veelen,
S. Laban,
M. V. D. Veer,
Marjet Roseboom,
S. Bres,
P. Grufman,
A. Ru,
H. Meiring,
...
A. D. Jong,
K. Franken,
Antoinette Teixeira,
R. Valentijn,
J. Drijfhout,
F. Koning,
M. Camps,
F. Ossendorp,
K. Kรคrre,
H. Ljunggren,
C. Melief,
R. Offringa
|
7 |
2006 |
7
๐
|
|
๐
|
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity
11 auth.
Nadine van Montfoort,
M. Camps,
Selina Khan,
D. Filippov,
Jimmy J. Weterings,
Janice M. Griffith,
...
H. Geuze,
T. van Hall,
J. Verbeek,
C. Melief,
F. Ossendorp
|
7 |
2009 |
7
๐
|
|
๐
|
Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28
7 auth.
T. van Hall,
A. Sijts,
M. Camps,
R. Offringa,
C. Melief,
P. Kloetzel,
...
F. Ossendorp
|
7 |
2000 |
7
๐
|
|
๐
|
Immune Complex-Loaded Dendritic Cells Are Superior to Soluble Immune Complexes as Antitumor Vaccine1
9 auth.
D. Schuurhuis,
Nadine van Montfoort,
A. Ioan-Facsinay,
Reshma Jiawan,
M. Camps,
J. Nouta,
...
C. Melief,
J. Verbeek,
F. Ossendorp
|
6 |
2006 |
6
๐
|
|
๐
|
The Inhibiting Fc Receptor for IgG, FcฮณRIIB, Is a Modifier of Autoimmune Susceptibility
19 auth.
P. Boross,
Victoria L. Arandhara,
Javier Martรญn-Ramรญrez,
M. SantiagoโRaber,
F. Carlucci,
R. Flierman,
Jos van der Kaa,
C. Breukel,
J. Claassens,
M. Camps,
...
E. Lubberts,
D. Salvatori,
M. Rastaldi,
F. Ossendorp,
M. Daha,
H. Cook,
S. Izui,
M. Botto,
J. Verbeek
|
6 |
2011 |
6
๐
|
|
๐
|
Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1
10 auth.
N. Beekman,
P. V. van Veelen,
T. van Hall,
A. Neisig,
A. Sijts,
M. Camps,
...
P. Kloetzel,
J. Neefjes,
C. Melief,
F. Ossendorp
|
6 |
2000 |
6
๐
|
|
๐
|
Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor LigandโPeptide Conjugates
13 auth.
Gijs G. Zom,
Selina Khan,
C. Britten,
V. Sommandas,
M. Camps,
N. Loof,
Chris Budden,
N. Meeuwenoord,
D. Filippov,
G. A. van der Marel,
...
H. Overkleeft,
C. Melief,
F. Ossendorp
|
6 |
2014 |
6
๐
|
|
๐ฌ
|
Combined Inhibition of TGF-ฮฒ Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
Heng Sheng Sow,
Jiang Ren,
M. Camps,
F. Ossendorp,
P. ten Dijke
|
6 |
2019 |
6
๐ฌ
|
